Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + ibuprofen is an oral combination therapy consisting of the beta-lactam antibiotic amoxicillin and the nonsteroidal anti-inflammatory drug ibuprofen, used together to treat bacterial infections while providing analgesic and antipyretic relief. Amoxicillin is a semi-synthetic penicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, leading to cell lysis and death in susceptible organisms, and is broadly used for respiratory, ear, sinus, skin, and genitourinary infections. Ibuprofen is a propionic acid derivative NSAID that non-selectively inhibits cyclooxygenase-1 and -2, reducing prostaglandin synthesis to relieve pain, inflammation, and fever without directly affecting amoxicillin’s antibacterial activity. The combination is commonly co-prescribed in outpatient and peri-procedural settings (e.g. dental or ENT infections) to manage both infection and associated symptoms, with attention to overlapping gastrointestinal and, in predisposed patients, renal or cardiovascular adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + ibuprofen.